Candidate gene association study of insulin signaling genes and Alzheimer's disease: Evidence for SOS2, PCK1, and PPARγ as susceptibility loci

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 144, Issue 4, 2007, Pages 508-516

  Hamilton, Gillian ^a,c   Proitsi, Petra ^a   Jehu, Luke ^b   Morgan, Angharad ^b   Williams, Julie ^b   O'Donovan, Michael C ^b   Owen, Michael J ^b   Powell, John F ^a   Lovestone, Simon ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Association; Genetics; Late onset Alzheimer's disease; Type II diabetes

Indexed keywords

INSULIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PCK1 GENE; PPARGAMMA GENE; PRIORITY JOURNAL; SEX DIFFERENCE; SOS2 GENE;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ATP-BINDING CASSETTE TRANSPORTERS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GREAT BRITAIN; HAPLOTYPES; HUMANS; INSULIN; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); POLYMORPHISM, SINGLE NUCLEOTIDE; POTASSIUM CHANNELS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PPAR GAMMA; RECEPTORS, DRUG; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION; SON OF SEVENLESS PROTEINS;

EID: 34250873382     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.30503     Document Type: Article

References (46)

1. Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, et al. 2000. The common PPAR gamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26(1):76-80.
2. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263-265.
3. Barroso I, Gurnell M, Crowley VEF, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TDM, Lewis H, Schafer AJ, et al. 1999. Dominant negative mutations in human PPAR gamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402(6764):880-883.
4. Barroso I, Luan J, Middelberg RPS, Harding AH, Franks PW, Jakes RW, Clayton D, Schafer AJ, O'Rahilly S, Wareham NJ. 2003. Candidate gene association study in type 2 diabetes indicates a role for genes involved in beta-cell function as well as insulin action. Plos Biol 1(1):41-55.
5. Beale EG, Hammer RF, Antoine B, Forest C. 2004. Disregulated glyceroneogenesis: PCK1 as a candidate diabetes and obesity gene. Trends Endocrinol Metab 15(3):129-135.
6. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. 2001. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125(1-2):279-284.
7. Bernardo A, Ajmone-Cat MA, Gasparini L, Ongini E, Minghetti L. 2005. Nuclear receptor peroxisome proliferator-activated receptor-gamma is activated in rat microglial cells by the anti-inflammatory drug HCT1026, a derivative of flurbiprofen. J Neurochem 92(4):895-903.
8. Bertram L, McQueen M, Mullin K, Blacker D, Tanzi R. 2006. The AlzGene Database. Alzheimer Research Forum. Available at http://www.alzgene.org. Accessed [17/02/06].
9. Borenstein AR, Copenhaver CI, Mortimer JA. 2006. Early-life risk factors for Alzheimer disease. Alzheimer Dis Assoc Disord 20(1):63-72.
10. Cao HN, van der Veer E, Ban MR, Hanley AJG, Zinman B, Harris SB, Young TK, Pickering JG, Hegele RA. 2004. Promoter polymorphism in PCK1 (phosphoenolpyruvate carboxykinase gene) associated with type 2 diabetes mellitus. J Clin Endocrinol Metab 89(2):898-903.
11. Craft S, Watson GS. 2004. Insulin and neurodegenerative disease: Shared and specific mechanisms. Lancet Neurol 3(3):169-178.
12. D'Abramo C, Massone S, Zingg J-M, Pizzuti A, Marambaud P, Dalla Piccola B, Azzi A, Marinari UM, Pronzato MA, Ricciarelli R. 2005. Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem J 391:693-698.
13. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. 1998. A Pro12Ala substitution in PPAR gamma 2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20(3):284-287.
14. Edland SD, Vriese FWD, Compton D, Smith GE, Ivnik R, Boeve BF, Tangalos EG, Petersen RC. 2003. Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: Evidence of effect modification by apolipoprotein E (APOE). Neurosci Lett 345(1):21-24.
15. Eftychi C, Howson JMM, Barratt BJ, Vella A, Payne F, Smyth DJ, Twells RCJ, Walker NM, Rance HE, Tuomilehto-Wolf E, et al. 2004. Analysis of the type 2 diabetes-associated single nucleotide polymorphisms in the genes IRS1, KCNJ11 and PPARG2 in type 1 diabetes. Diabetes 53(3):870-873.
16. Florez JC, Hirschhorn J, Altshuler D. 2003. The inheritebasis odiabetes mellitus: Implications for the genetic analysis of complex traits. Ann Rev Genomics Hum Genet 4:257-291.
17. Gasparini L, Netzer WJ, Greengard P, Xu HX. 2002. Does insulin dysfunction play a role in Alzheimer's disease? Trends Pharmacol Sci 23(6):288-293.
18. Hahn LW, Ritchie MD, Moore JH. 2001. Power of multifactor dimensionality reduction (MDR) for identifying gene-gene and gene-environment interactions. Am J Hum Genet 69(4):1174.
19. Hamilton G, Samedi F, Knight J, Archer N, Foy C, Walter S, Turic D, Jehu L, Moore P, Hollingworth P, et al. 2006. Polymorphisms in the phosphate and tensin homolog gene are not associated with late-onset Alzheimer's disease. Neurosci Lett 401(1-2):77-80.
20. Hara M, Alcoser SY, Qaadir A, Beiswenger KK, Cox NJ, Ehrmann DA. 2002. Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPAR gamma gene. J Clin Endocrinol Metab 87(2):772-775.
21. Hegele RA, Cao H, Harris SB, Zinman B, Hanley AJG, Anderson CM. 2000. Peroxisome proliferator-activated receptor-gamma2 P12A and type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab 85(5):2014-2019.
22. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'Banion K, Klockgether T, Van Leuven F, Landreth GE. 2005. Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta 1-42 levels in APPV717I transgenic mice. Brain 128(Pt 6):1442-1453.
23. Hixson JE, Vernier DT. 1990. Restriction isotyping of human apolipoprotein-E by gene amplification and cleavage with Hhai. J Lipid Res 31(3):545-548.
24. Hoyer S. 2004. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490(1-3):115-125.
25. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang FS, Cole G. 1996. Correlative memory deficits, A beta elevation, and amyloid plaques in transgenic mice. Science 274(5284):99-102.
26. Inestrosa NC, Godoy JA, Quintanilla RA, Koenig CS, Bronfman M. 2005. Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: Role of Wnt signaling. Exp Cell Res 304(1):91-104.
27. Jung HS, Youn BS, Cho YM, Yu KY, Park HJ, Shin CS, Kim SY, Lee HK, Park KS. 2005. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism 54(3):314-320.
28. Kuusisto J, Koivisto K, Mykkanen L, Helkala EL, Vanhanen M, Hanninen T, Kervinen K, Kesaniemi YA, Riekkinen PJ, Laakso M. 1997. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: Cross sectional population based study. Br Med J 315(7115):1045-1049.
29. Lee AJ, McInerney PJ, Mullins PR. 1984. STATCALC - and integrated statistics system for the Apple-II microcomputer. Comput Programs Biomed 18(3):265-272.
30. Lee CH, Olson P, Evans RM. 2003. Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144(6):2201-2207.
31. Liu JJ, Farmer SR. 2004. Regulating the balance between peroxisome proliferator-activated receptor gamma and beta-catenin signaling during adipogenesis - A glycogen synthase kinase 3 beta phosphorylation-defective mutant of beta-catenin inhibits expression of a subset of adipogenic genes. J Biol Chem 279(43):45020-45027.
32. Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martinez A, Perez-Castillo A. 2005. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator- activated receptor gamma activation. J Biol Chem
33. Pedersen WA, McMillan PJ, Kulstad JJ, Leverenz JB, Craft S, Haynatzki GR. 2006. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 199(2):265-273.
34. Peila R, Rodriguez BL, Launer LJ. 2002. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies - The Honolulu-Asia Aging Study. Diabetes 51(4):1256-1262.
35. Porter JR, Barrett TG. 2005. Monogenic syndromes of abnormal glucose homeostasis: Clinical review and relevance to the understanding of the pathology of insulin resistance and beta cell failure. J Med Genet 42(12):893-902.
36. Prince JA, Feuk L, Gu HF, Johansson B, Gatz M, Blennow K, Brookes AJ. 2003. Genetic variation in a haplotype block spanning IDE influences Alzheimer disease. Hum Mutat 22(5):363-371.
37. Purcell S, Cherny SS, Sham PC. 2003. Genetic power calculator: Design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19(1):149-150.
38. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, Evert BO, Dumitrescu-Ozimek L, Thal DR, Landreth G, et al. 2006. Nonsteroidal anti-inflammatory drugs repress B-secretase gene promoter activity by the activation of PPARG. Proc Natl Acad Sci USA 103(2):443-448.
39. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, Farhang-Fallah J, Dikkes P, Warot XM, Rio C, et al. 2003. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 23(18):7084-7092.
40. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, Kondo T, Alber J, Galldiks N, Kustermann E, et al. 2004. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci USA 101(9):3100-3105.
41. Schulingkamp RJ, Pagano TC, Hung D, Raffa RB. 2000. Insulin receptors and insulin action in the brain: Review and clinical implications. Neurosci Biobehav Rev 24(8):855-872.
42. Skol AD, Scott LJ, Abecasis GR, Boehnke M. 2006. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 38(2):209-213.
43. Watson GS, Craft S. 2004. Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 490(1-3):97-113.
44. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana SFMA, Kulstad JJ, Green PS, Cook DG, Kahn SE, et al. 2005. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study. Am J Geriatr Psychiatry 13(11):950-958.
45. Wigginton JE, Abecasis GR. 2005. PEDSTATS: Descriptive statistics, graphics and quality assessment for gene mapping data. Bioinformatics 21(16):3445-3447.
46. Williams CM. 2004. Lipid metabolism in women. Proc Nutr Soc 63:153-160.